Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

Core Insights - Voyager Therapeutics reported a quarterly loss of $0.57 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.48, marking an earnings surprise of -18.75% [1] - The company generated revenues of $5.2 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 55.43%, and a significant decline from $29.58 million in the same quarter last year [2] - Voyager Therapeutics shares have decreased by approximately 40.4% year-to-date, contrasting with the S&P 500's gain of 7.1% [3] Company Performance - Over the last four quarters, Voyager Therapeutics has only surpassed consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.48 on revenues of $11.24 million, and for the current fiscal year, it is -$1.99 on revenues of $44.08 million [7] - The estimate revisions trend for Voyager Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]